GlassScriptPhysician profile
Elizabeth A Buchinsky
NPI 1164427118
$2,049.94
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $520 · 2020: $481 · 2021: $313 · 2022: $394 · 2023: $319 · 2024: $22.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $340.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $312.89 | 2019-2023 | |
| Lilly USA, LLC | $250.10 | 2019-2023 | Mounjaro, Trulicity |
| Abbvie INC. | $188.08 | 2021-2023 | Vraylar |
| Cranial Technologies, INC | $169.61 | 2019-2022 | |
| Amarin Pharma, INC. | $124.07 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $85.76 | 2019-2022 | |
| Glaxosmithkline, LLC. | $83.57 | 2021-2023 | Trelegy Ellipta |
| Esperion Therapeutics, INC. | $82.14 | 2020-2021 | |
| Allergan, INC. | $77.39 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $74.94 | 2019-2023 | Breztri |
| Amgen INC. | $60.20 | 2019 | |
| Supernus Pharmaceuticals, INC. | $46.79 | 2021 | |
| Neos Therapeutics, LP | $44.54 | 2019-2020 | |
| Abbott Laboratories | $38.73 | 2019-2022 | |
| Seqirus USA INC | $35.97 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $33.56 | 2023 | Gvoke Hypopen |
| Novo Nordisk INC | $30.47 | 2020-2021 | |
| Genentech USA, INC. | $29.74 | 2020 | |
| Sanofi Pasteur INC. | $28.02 | 2019-2021 | |
| Exact Sciences Corporation | $24.99 | 2023 | Cologuard Collection Kit |
| Akebia Therapeutics INC | $23.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.57 | 2019 | |
| Dynasplint Systems INC. | $22.00 | 2024 | Dynasplint |
| Ironshore Pharmaceuticals INC. | $20.19 | 2019 | |
| Janssen Pharmaceuticals, INC | $19.77 | 2019 | |
| Mylan Specialty L.P. | $18.15 | 2020 | |
| Acerus Pharmaceuticals Corporation | $17.98 | 2022 | |
| Clarus Therapeutics INC. | $17.21 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.54 | 2022 | |
| Eisai INC. | $13.84 | 2020 | |
| Arbor Pharmaceuticals, INC. | $13.63 | 2021 | |
| Amag Pharmaceuticals, INC. | $12.50 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Buchinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.